Platform Development for Cell & Gene Therapy
Are you looking to better understand the challenges in developing robust processes for cell and gene therapy manufacturing? Do you have in house process development capabilities? Are you responsible for key outsourcing decisions, problem solving, or finding new solutions to reach your next milestone quickly?
Join us to hear from industry experts in an engaging panel discussion with peer-to-peer insights. Make new connections and access advice and expertise from folks who have tackled these challenges many times before.
Custom media development for C>
• Top-down vs. bottom-up approach
• Mass spectrometry and multivariate statistical analysis
• DoE formulations screening
• Animal component free case study
Cell line Development for Viral Vector Production
• Cell line screening
• Suspension adaptation
• Transfer vector integration techniques
• Viral Titering
Who should attend?
• Cell and gene therapy process development
• Interested in stem cell biology & viral vector manufacturing
• Manufacturing directors and leaders
• Scientific and technology transfer managers
Speakers:
Philip G. Vanek, Ph.D.Partner at Gamma Biosciences
Phil is a passionate advocate for regenerative medicine and the role it will play in treating diseases as global healthcare systems transition to precision health models. An entrepreneurial and strategic international business leader, Phil has led marketing, business development, and innovation in start-up and established biotechnology companies. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center. Phil held leadership positions at Life Technologies, Atto Bioscience, BD Biosciences, and Lonza Bioscience before joining GE Healthcare.
His business and academic experiences give him a unique perspective of the global opportunities and challenges of the biotechnology industry.
Gary M. Pigeau, PhD Director Centre for Advanced Therapeutic Cell Technologies
Gary Pigeau joined GE Healthcare in 2016 and is Director of the Centre for Advanced Therapeutic Cell Technologies (CATCT) at CCRM in Toronto, Ontario. He received his Ph.D. in Biotechnology from Brock University and completed a postdoctoral fellowship at the University of Alberta, with a visiting scientist appointment at the University of Oxford. One of Gary’s first projects at CATCT was design oversight of the custom media development infrastructure. The CATCT collaboration has a focus on biology support for New Product Introductions, internal technology development projects and contract process development services in cell and gene therapy.
Steven Loo-Yong-Kee, MEng Development Engineer/Scientist BRIDGE @ CCRM
Steven is a senior development associate at CCRM focusing on improving manufacturing and accelerating commercialization of viral vectors and immunotherapies. His experience includes developing and optimizing a semi-automated closed CAR-T manufacturing process utilizing commercially available cGMP media, reagents and equipment, as well as evaluating serum-free suspension cell lines and transient transfection methods for scalable for LV and AAV production.